Innovent BioORIENT-31 studies that sindilizumab combined with chemotherapy in EGFR mutant non-squamous non-small cell lung cancer obtained a significant prolongation of PFS

Cinda Biopharma Group (HKEx: 01801), a biopharmaceutical company dedicated to the development, production and marketing of innovative drugs in the field of major diseases such as oncology, self-immunity, metabolism, ophthalmology and other major diseases, announced the combination or non-combination ® of Dabshu ® (Sindili Monoclonal Antibody Injection) in the form of an oral report (Abstract No.

The results of the second interim analysis showed that in the population of intent therapy (ITT), based on the Independent Imaging Evaluation Board (IRRC) assessment, the mPFS (95% CI) of Daboshu ® (sindili maclizumab injection) + Dayoutong ® (bevacizumab analogue) combined with chemotherapy group (trial group A), Daboshu ® (sindili mabumab injection) combined with chemotherapy group (trial group B) and chemotherapy group (control group C) were 7.

Professor Lu Shun, the main investigator of the ORIENT-31 study, from the Department of Oncology of Shanghai Chest Hospital, said: "EGFR-TKI targeted therapy is the preferred treatment plan for patients with EGFR-sensitive mutation NSCLC, but after using TKI drugs, almost all patients will eventually appear resistant and lead to disease progression, and the efficacy of platinum-containing chemotherapy after drug resistance is not ideal, so the problem of drug resistance and the choice of treatment after drug resistance have become the main concerns of clinicians

Dr.